Geron | GERN - Cash And Equivalent


Geron reported $62.64M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Amgen USD 13.99B 1.95B Jun/2026
Bio Techne USD 264.71M 54.89M Jun/2026
Cassava Sciences USD 86.57M 8.93M Mar/2026
Cytokinetics USD 255.27M 125.43M Jun/2026
Exelixis USD 281.45M 55.3M Jun/2026
Genmab DKK 1.5B 18M Jun/2026
Geron USD 62.64M 6.25M Jun/2026
Gilead Sciences USD 7.63B 64M Mar/2026
Incyte USD 3.98B 33.45M Jun/2026
MacroGenics USD 113.91M 47.39M Jun/2026
Novartis USD 7.62B 739M Jun/2026
Novavax USD 191.46M 36.9M Jun/2026